Effect of Reslizumab on small airways in asthma. RESSAPEA
Phase 4
Recruiting
- Conditions
- air trappingAsthma10006436
- Registration Number
- NL-OMON55433
- Lead Sponsor
- Academisch Medisch Centrum
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 33
Inclusion Criteria
severe asthma; Blood eosinophil counts >=0.4 x 10E9/L despite adequate
treatment with high doses of inhaled corticosteroids (>1000mcg/day fluticasone
equivalent)
Exclusion Criteria
Subjects with other conditions that could lead to elevated eosinophils such as
Hyper eosinophilic Syndromes, including Churg-Strauss Syndrome, or Eosinophilic
Esophagitis.
malignancies; use of other monoclonals (except omalizumab)
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method